The CHDI Foundation, Inc., is a United States–based non-profit biomedical foundation that aims to "rapidly discover and develop drugs that delay or slow the progression of Huntington's disease",[4] a neurodegenerative genetic disorder that affects muscle coordination and leads to cognitive decline.

According to Simon Noble, CHDI's Director of Scientific Communication, the logo represents the groundedness of the Foundation, the hereditary nature of HD, the interconnectedness of biological pathways and the medicinal chemistry of drug development.

[10] Rather than supplying grants, CHDI enters into research contracts with its collaborators, and exerts a managerial role in addition to providing financial support.

[1] In a 2007 Nature news feature, CHDI's then senior scientific advisor Allan Tobin stated, "Ninety-five per cent of science works on the principle that the best thing to do is to let good scientists follow their noses ...

"[1] CHDI's annual spend is unknown, but it is the largest single funder of Huntington's disease research: according to a Nature news feature, it spent $50 million in 2006.